Mersana Therapeutics - MRSN Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MRSN shares.
View MRSN analyst ratings or view top-rated stocks.

4 Wall Street analysts have issued 12 month price targets for Mersana Therapeutics' shares. Their MRSN share price forecasts range from $12.00 to $20.00. On average, they anticipate the company's stock price to reach $16.25 in the next year. This suggests a possible upside of 155.5% from the stock's current price.
View analysts price targets for MRSN or view top-rated stocks among Wall Street analysts.

Mersana Therapeutics' stock was trading at $6.22 at the beginning of 2022. Since then, MRSN shares have increased by 2.3% and is now trading at $6.36.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our MRSN earnings forecast.

Mersana Therapeutics, Inc. (NASDAQ:MRSN) posted its quarterly earnings results on Monday, November, 7th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.03) by $0.58. The firm had revenue of $5.57 million for the quarter, compared to analysts' expectations of $38.57 million. Mersana Therapeutics had a negative trailing twelve-month return on equity of 171.23% and a negative net margin of 1,749.59%.

3 employees have rated Mersana Therapeutics Chief Executive Officer Anna Protopapas on Glassdoor.com. Anna Protopapas has an approval rating of 100% among the company's employees. This puts Anna Protopapas in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mersana Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Ovid Therapeutics (OVID), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Marvell Technology (MRVL), Inovio Pharmaceuticals (INO), DocuSign (DOCU), Immunomedics (IMMU) and Marinus Pharmaceuticals (MRNS).

(MRSN) raised $75 million in an initial public offering (IPO) on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

Mersana Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (7.10%), Vanguard Group Inc. (4.39%), Bellevue Group AG (4.09%), State Street Corp (4.07%), Nuveen Asset Management LLC (1.27%) and Two Sigma Advisers LP (1.12%). Insiders that own company stock include Alejandra Carvajal, Andrew A F Hack, Anna Protopapas, Arvin Yang, Ashish Mandelia, Eva M Jack, Lawrence M Alleva, Lawrence M Alleva, Scott D Sandell, Timothy B Lowinger and Tushar Misra.
View institutional ownership trends.

Shares of MRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MRSN stock can currently be purchased for approximately $6.36.

Mersana Therapeutics (NASDAQ:MRSN) has a market capitalization of $634.54 million and generates $40,000.00 in revenue each year. The company earns $-170,060,000.00 in net income (profit) each year or ($2.43) on an earnings per share basis.

The company employs 169 workers across the globe.

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The official website for the company is www.mersana.com. The company can be reached via phone at (617) 498-0020 or via email at ir@mersana.com.